News|Articles|November 16, 2026

FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival Data

Author(s)Alex Biese
Fact checked by: By ONN Staff

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

The FDA has issued a complete response letter (CRL) for the biologics license application (BLA) seeking approval of ivonescimab plus platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) whose disease progressed after EGFR tyrosine kinase inhibitor (TKI) therapy, according to a November 15, 2026, announcement from developer Summit Therapeutics.1

The agency stated that substantial evidence of effectiveness is not established without a statistically significant overall survival (OS) improvement, and that the progression-free survival (PFS) benefit alone does not support a positive benefit-risk profile.1

Ivonescimab, a PD-1 x VEGF bispecific antibody, was approved in China in May 2024; no agent in this class is approved in the United States.1 According to the release, the BLA "cannot be approved in its present form"; the announcement did not describe plans for an FDA meeting or resubmission.1

What did the HARMONi trial evaluate?

The application was supported by the global, randomized, double-blind, placebo-controlled phase 3 HARMONi trial (NCT06396065), which enrolled 438 patients with stage IIIB/IIIC or IV nonsquamous EGFR-mutated NSCLC and an ECOG performance status of 0 or 1 whose disease progressed on a third-generation EGFR TKI.2,3 Patients received ivonescimab 20 mg/kg intravenously or placebo every 3 weeks, each with carboplatin (AUC 5 for 4 cycles) and pemetrexed 500 mg/m2 every 3 weeks.3 PFS by independent review and OS were dual primary end points. Summit sponsored the trial; 165 patients enrolled in North America and Europe.3,4

What did HARMONi show for PFS and OS?

The primary analysis, published in The Lancet Oncology, met the PFS end point but not the OS end point.2,3

  • Median PFS: 6.8 vs 4.4 months (HR, 0.52; 95% CI, 0.41-0.66; P < .0001)
  • 6-month PFS rate: 54.0% vs 34.7%; 12-month PFS rate: 25.4% vs 8.3%
  • Objective response rate: 45% vs 34%
  • Median OS: 16.8 vs 14.0 months (HR, 0.79; 95% CI, 0.62-1.01; P = .057)

At a June 2026 data cutoff, a post hoc analysis showed an OS HR of 0.76 in the full intention-to-treat population and in the Western subgroup.4 Summit reported the same HR in Asian patients.1 Post hoc analyses do not carry the statistical weight of a prespecified end point.

What safety findings should nurses know about?

Treatment-related adverse events (TRAEs) of any grade occurred in 95.0% of patients in the ivonescimab arm vs 93.1% in the placebo arm. Grade 3 or higher adverse events occurred in 50.0% vs 42.2%, and serious adverse events in 28.0% vs 15.1%.3 TRAEs led to discontinuation in 16 patients (7.3%) vs 11 patients (5.0%), and 4 patients (1.8%) vs 5 patients (2.3%) died of TRAEs.1

The most common TRAEs were hematologic, including anemia (49.1% vs 56.4%) and decreased neutrophil count (42.7% vs 42.2%).3 Grade 3 or higher immune-related adverse events occurred in 9.6% vs 6.0% of patients, and grade 3 or higher VEGF-related TRAEs in 7.3% vs 3.2%. In the ivonescimab arm, any-grade proteinuria occurred in 13.8%, hypertension in 13.3%, hemorrhage in 10.6%, and hypothyroidism in 8.3%.3

How did Summit respond to the CRL?

"We are disappointed for patients and their families awaiting additional treatment options in this setting," Robert W. Duggan, chairman and co-CEO of Summit Therapeutics, said in the release.1

"Every additional treatment option matters," added Maky Zanganeh, president and co-CEO. "It represents another opportunity for patients and their families, especially those who have exhausted existing therapies or have limited alternatives."1

Where does ivonescimab go from here?

The HARMONi data followed results from the China-only phase 3 HARMONi-A trial, in which ivonescimab plus chemotherapy extended median PFS to 7.1 vs 4.8 months with placebo plus chemotherapy (HR, 0.46) among 322 patients previously treated with EGFR TKIs.5 In advanced squamous NSCLC, the phase 3 HARMONi-6 trial showed a PFS benefit for ivonescimab plus chemotherapy vs tislelizumab (Tevimbra) plus chemotherapy (HR, 0.60).6

Summit said development continues, including the phase 3 HARMONi-3 and HARMONi-7 trials in first-line NSCLC and studies in colorectal, urothelial, and renal cell cancers.1

What are the key takeaways for oncology nurses?

  • Ivonescimab is not FDA approved; access in the United States remains limited to clinical trials.1
  • Patients progressing on a third-generation EGFR TKI may ask about the agent; trial referral is the current route.
  • In HARMONi, the PFS improvement did not translate into a statistically significant OS benefit in the primary analysis, a distinction worth explaining during shared decision-making.3
  • For patients receiving ivonescimab on a trial, monitoring includes blood counts, blood pressure, urine protein, bleeding, and thyroid function, given the hematologic, VEGF-related, and immune-related events reported.3
  • Serious adverse events were more common with ivonescimab (28.0% vs 15.1%), reinforcing education on reporting new symptoms.3

References

  1. Summit Therapeutics provides update regarding ivonescimab biologics license application. News release. Summit Therapeutics. November 15, 2026. Accessed November 16, 2026. https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx
  2. Le X, Passaro A, Zhao Y, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026;27(9):1094-1109. doi:10.1016/S1470-2045(26)00282-2
  3. Chan A. Ivonescimab plus chemo after third-generation TKI generates improved PFS in EGFR-mutated NSCLC. OncLive. September 7, 2025. Accessed November 16, 2026. https://www.onclive.com/view/ivonescimab-plus-chemo-after-third-generation-tki-generates-improved-pfs-in-egfr-mutated-nsclc
  4. Ivonescimab plus chemotherapy sustains OS benefit across Western and Asian patients in pretreated EGFR-mutated NSCLC. OncLive. July 22, 2026. Accessed November 16, 2026. https://www.onclive.com/view/ivonescimab-plus-chemotherapy-sustains-os-benefit-in-pretreated-egfr-mutated-nsclc
  5. Fabbricatore R. Ivonescimab plus chemo advances PFS in NSCLC previously treated with EGFR TKIs. Oncology Nursing News. July 31, 2024. Accessed November 16, 2026. https://www.oncnursingnews.com/view/ivonescimab-plus-chemo-advances-pfs-in-nsclc-previously-treated-with-egfr-tkis
  6. Rosa K. Ivonescimab plus chemo extends PFS in advanced squamous NSCLC. Oncology Nursing News. October 20, 2025. Accessed November 16, 2026. https://www.oncnursingnews.com/view/ivonescimab-plus-chemo-extends-pfs-in-advanced-squamous-nsclc

Related to this article